3bzu
From Proteopedia
(New page: '''Unreleased structure''' The entry 3bzu is ON HOLD until Jan 18 2010 Authors: Min, X., Sudom, A., Xu, H., Wang, Z., Walker, N.P. Description: Crystal structure of human 11-beta-hydro...) |
|||
| Line 1: | Line 1: | ||
| - | + | [[Image:3bzu.jpg|left|200px]] | |
| - | The | + | <!-- |
| + | The line below this paragraph, containing "STRUCTURE_3bzu", creates the "Structure Box" on the page. | ||
| + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | ||
| + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | ||
| + | or leave the SCENE parameter empty for the default display. | ||
| + | --> | ||
| + | {{STRUCTURE_3bzu| PDB=3bzu | SCENE= }} | ||
| - | + | '''Crystal structure of human 11-beta-hydroxysteroid dehydrogenase(HSD1) in complex with NADP and thiazolone inhibitor''' | |
| - | Description: Crystal structure of human 11-beta-hydroxysteroid dehydrogenase(HSD1) in complex with NADP and thiazolone inhibitor | ||
| + | ==Overview== | ||
| + | 11Beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid action and inhibition of this enzyme is a viable therapeutic strategy for the treatment of type 2 diabetes and the metabolic syndrome. Here, we report a potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor with a binding mode elucidated from the co-crystal structure with the human 11beta-hydroxysteroid dehydrogenase type 1. The inhibitor is bound to the steroid-binding pocket making contacts with the catalytic center and the solvent channel. The inhibitor binding is facilitated by two direct hydrogen bond interactions involving Tyrosine183 of the catalytic motif Tyr-X-X-X-Lys and Alanine172. In addition, the inhibitor makes many hydrophobic interactions with both the enzyme and the co-factor nicotinamide adenine dinucleotide phosphate (reduced). In lean C57BL/6 mice, the compound inhibited both the in vivo and ex vivo 11beta-hydroxysteroid dehydrogenase type 1 activities in a dose-dependent manner. The inhibitory effects correlate with the plasma compound concentrations, suggesting that there is a clear pharmacokinetic and pharmacodynamic relationship. Moreover, at the same doses used in the pharmacokinetic/pharmacodynamic studies, the inhibitor did not cause the activation of the hypothalamic-pituitary-adrenal axis in an acute mouse model, suggesting that this compound exhibits biological effects with minimal risk of activating the hypothalamic-pituitary-adrenal axis. | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jun 11 | + | ==About this Structure== |
| + | 3BZU is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3BZU OCA]. | ||
| + | |||
| + | ==Reference== | ||
| + | Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor., Hale C, Veniant M, Wang Z, Chen M, McCormick J, Cupples R, Hickman D, Min X, Sudom A, Xu H, Matsumoto G, Fotsch C, St Jean DJ Jr, Wang M, Chem Biol Drug Des. 2008 Jan;71(1):36-44. Epub 2007 Dec 7. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/18069989 18069989] | ||
| + | [[Category: 11-beta-hydroxysteroid dehydrogenase]] | ||
| + | [[Category: Homo sapiens]] | ||
| + | [[Category: Single protein]] | ||
| + | [[Category: Min, X.]] | ||
| + | [[Category: Sudom, A.]] | ||
| + | [[Category: Walker, N P.]] | ||
| + | [[Category: Wang, Z.]] | ||
| + | [[Category: Xu, H.]] | ||
| + | [[Category: 11beta hydroxysteroid dehydrogenase]] | ||
| + | [[Category: Endoplasmic reticulum]] | ||
| + | [[Category: Glycoprotein]] | ||
| + | [[Category: Lipid metabolism]] | ||
| + | [[Category: Membrane]] | ||
| + | [[Category: Microsome]] | ||
| + | [[Category: Nadp]] | ||
| + | [[Category: Oxidoreductase]] | ||
| + | [[Category: Polymorphism]] | ||
| + | [[Category: Signal-anchor]] | ||
| + | [[Category: Steroid metabolism]] | ||
| + | [[Category: Transmembrane]] | ||
| + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jun 11 10:48:00 2008'' | ||
Revision as of 07:48, 11 June 2008
Crystal structure of human 11-beta-hydroxysteroid dehydrogenase(HSD1) in complex with NADP and thiazolone inhibitor
Overview
11Beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid action and inhibition of this enzyme is a viable therapeutic strategy for the treatment of type 2 diabetes and the metabolic syndrome. Here, we report a potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor with a binding mode elucidated from the co-crystal structure with the human 11beta-hydroxysteroid dehydrogenase type 1. The inhibitor is bound to the steroid-binding pocket making contacts with the catalytic center and the solvent channel. The inhibitor binding is facilitated by two direct hydrogen bond interactions involving Tyrosine183 of the catalytic motif Tyr-X-X-X-Lys and Alanine172. In addition, the inhibitor makes many hydrophobic interactions with both the enzyme and the co-factor nicotinamide adenine dinucleotide phosphate (reduced). In lean C57BL/6 mice, the compound inhibited both the in vivo and ex vivo 11beta-hydroxysteroid dehydrogenase type 1 activities in a dose-dependent manner. The inhibitory effects correlate with the plasma compound concentrations, suggesting that there is a clear pharmacokinetic and pharmacodynamic relationship. Moreover, at the same doses used in the pharmacokinetic/pharmacodynamic studies, the inhibitor did not cause the activation of the hypothalamic-pituitary-adrenal axis in an acute mouse model, suggesting that this compound exhibits biological effects with minimal risk of activating the hypothalamic-pituitary-adrenal axis.
About this Structure
3BZU is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor., Hale C, Veniant M, Wang Z, Chen M, McCormick J, Cupples R, Hickman D, Min X, Sudom A, Xu H, Matsumoto G, Fotsch C, St Jean DJ Jr, Wang M, Chem Biol Drug Des. 2008 Jan;71(1):36-44. Epub 2007 Dec 7. PMID:18069989 Page seeded by OCA on Wed Jun 11 10:48:00 2008
Categories: 11-beta-hydroxysteroid dehydrogenase | Homo sapiens | Single protein | Min, X. | Sudom, A. | Walker, N P. | Wang, Z. | Xu, H. | 11beta hydroxysteroid dehydrogenase | Endoplasmic reticulum | Glycoprotein | Lipid metabolism | Membrane | Microsome | Nadp | Oxidoreductase | Polymorphism | Signal-anchor | Steroid metabolism | Transmembrane
